Jump to content

Vutiglabridin: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
OAbot (talk | contribs)
Bots
433,972 edits
m Open access bot: pmc, doi updated in citation with #oabot.
No edit summary
Line 1: Line 1:
{{Orphan|date=December 2023}}
{{Orphan|date=December 2023}}
{{Infobox drug
| drug_name =
| INN =
| type = <!-- empty -->
| image = Vutiglabridin.svg
| alt =
| caption =
<!-- Clinical data -->
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix =
<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 -->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment =
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status = Investigational<!-- For countries not listed above -->
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
<!-- Identifiers -->
| CAS_number = 1800188-47-9
| PubChem = 118204185
| UNII = = 7AWD9J49UP
| DrugBank =
<!-- Chemical and physical data -->
| IUPAC_name = 2-(8,8-Dimethyl-3,4,9,10-tetrahydro-2''H''-pyrano[2,3-''h'']chromen-3-yl)-5-ethoxyphenol
| C = 22 | H = 26 | O = 4
}}


'''Vutiglabridin''' (HSG4112) is an experimental anti-obesity drug that is a synthetic structural analog of [[glabridin]].<ref>{{cite journal |last1=Hyeon |first1=Jooseung |last2=Lee |first2=Jihan |last3=Kim |first3=Eunju |last4=Lee |first4=Hyeong Min |last5=Kim |first5=Kwang Pyo |last6=Shin |first6=Jaejin |last7=Park |first7=Hyung Soon |last8=Lee |first8=Yun-Il |last9=Nam |first9=Chang-Hoon |title=Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions |journal=Experimental Gerontology |date=October 2023 |volume=181 |pages=112269 |doi=10.1016/j.exger.2023.112269|doi-access=free }}</ref><ref>{{cite journal |last1=Na |first1=Joo Young |last2=Yoon |first2=Deok Yong |last3=Yoo |first3=Hyounggyoon |last4=Lee |first4=SeungHwan |last5=Yu |first5=Kyung‐Sang |last6=Jang |first6=In‐Jin |last7=Yoo |first7=Sang‐Ku |last8=Kim |first8=Youngah |last9=Oh |first9=Jaeseong |title=Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study |journal=Clinical and Translational Science |date=November 2022 |volume=15 |issue=11 |pages=2744–2757 |doi=10.1111/cts.13401 |url=https://doi.org/10.1111/cts.13401 |language=en |issn=1752-8054|pmc=9652434 }}</ref><ref>{{cite journal |last1=Choi |first1=Leo Sungwong |last2=Jo |first2=In Geun |last3=Kang |first3=Ku Suk |last4=Im |first4=Jeong Ho |last5=Kim |first5=Jiyoung |last6=Kim |first6=Jinyoung |last7=Chung |first7=Jin Wook |last8=Yoo |first8=Sang-Ku |title=Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity |journal=International Journal of Obesity |date=January 2021 |volume=45 |issue=1 |pages=130–142 |doi=10.1038/s41366-020-00686-1 |url=https://www.nature.com/articles/s41366-020-00686-1 |language=en |issn=1476-5497|doi-access=free }}</ref>
'''Vutiglabridin''' ('''HSG4112''') is an experimental anti-obesity drug that is a synthetic structural analog of [[glabridin]].<ref>{{cite journal |last1=Hyeon |first1=Jooseung |last2=Lee |first2=Jihan |last3=Kim |first3=Eunju |last4=Lee |first4=Hyeong Min |last5=Kim |first5=Kwang Pyo |last6=Shin |first6=Jaejin |last7=Park |first7=Hyung Soon |last8=Lee |first8=Yun-Il |last9=Nam |first9=Chang-Hoon |title=Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions |journal=Experimental Gerontology |date=October 2023 |volume=181 |pages=112269 |doi=10.1016/j.exger.2023.112269|doi-access=free }}</ref><ref>{{cite journal |last1=Na |first1=Joo Young |last2=Yoon |first2=Deok Yong |last3=Yoo |first3=Hyounggyoon |last4=Lee |first4=SeungHwan |last5=Yu |first5=Kyung‐Sang |last6=Jang |first6=In‐Jin |last7=Yoo |first7=Sang‐Ku |last8=Kim |first8=Youngah |last9=Oh |first9=Jaeseong |title=Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study |journal=Clinical and Translational Science |date=November 2022 |volume=15 |issue=11 |pages=2744–2757 |doi=10.1111/cts.13401 |url=https://doi.org/10.1111/cts.13401 |language=en |issn=1752-8054|pmc=9652434 }}</ref><ref>{{cite journal |last1=Choi |first1=Leo Sungwong |last2=Jo |first2=In Geun |last3=Kang |first3=Ku Suk |last4=Im |first4=Jeong Ho |last5=Kim |first5=Jiyoung |last6=Kim |first6=Jinyoung |last7=Chung |first7=Jin Wook |last8=Yoo |first8=Sang-Ku |title=Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity |journal=International Journal of Obesity |date=January 2021 |volume=45 |issue=1 |pages=130–142 |doi=10.1038/s41366-020-00686-1 |url=https://www.nature.com/articles/s41366-020-00686-1 |language=en |issn=1476-5497|doi-access=free }}</ref>


==References==
==References==
Line 7: Line 64:


[[Category:Experimental anti-obesity drugs]]
[[Category:Experimental anti-obesity drugs]]
[[Category:Phenols]]

Revision as of 02:23, 14 December 2023

Vutiglabridin
Legal status
Legal status
  • Investigational
Identifiers
  • 2-(8,8-Dimethyl-3,4,9,10-tetrahydro-2H-pyrano[2,3-h]chromen-3-yl)-5-ethoxyphenol
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC22H26O4
Molar mass354.446 g·mol−1

Vutiglabridin (HSG4112) is an experimental anti-obesity drug that is a synthetic structural analog of glabridin.[1][2][3]

References

  1. ^ Hyeon, Jooseung; Lee, Jihan; Kim, Eunju; Lee, Hyeong Min; Kim, Kwang Pyo; Shin, Jaejin; Park, Hyung Soon; Lee, Yun-Il; Nam, Chang-Hoon (October 2023). "Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions". Experimental Gerontology. 181: 112269. doi:10.1016/j.exger.2023.112269.
  2. ^ Na, Joo Young; Yoon, Deok Yong; Yoo, Hyounggyoon; Lee, SeungHwan; Yu, Kyung‐Sang; Jang, In‐Jin; Yoo, Sang‐Ku; Kim, Youngah; Oh, Jaeseong (November 2022). "Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study". Clinical and Translational Science. 15 (11): 2744–2757. doi:10.1111/cts.13401. ISSN 1752-8054. PMC 9652434.
  3. ^ Choi, Leo Sungwong; Jo, In Geun; Kang, Ku Suk; Im, Jeong Ho; Kim, Jiyoung; Kim, Jinyoung; Chung, Jin Wook; Yoo, Sang-Ku (January 2021). "Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity". International Journal of Obesity. 45 (1): 130–142. doi:10.1038/s41366-020-00686-1. ISSN 1476-5497.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vutiglabridin&oldid=1189798135"